H. Tatum

发表

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

O. Weiland, P. Thuluvath, G. Everson, 2014, Gut.

Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid.

William M. Lee, William M Lee, E. Schiff, 2011, Journal of virological methods.

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

P. Marcellin, P. Thuluvath, G. Everson, 2014, Gastroenterology.

A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

P. Thuluvath, E. Lawitz, R. Ghalib, 2015, Journal of viral hepatitis.

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

G. Dore, S. Pol, A. Tran, 2013 .

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

J. Chan, D. Rockey, P. Thuluvath, 2020, Journal of hepatology.

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

P. Thuluvath, G. Everson, S. Pol, 2011 .

1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL

G. Everson, S. Pol, C. Hézode, 2010 .

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Ulysses Diva, Vinod K Rustgi, P. Thuluvath, 2012, The Lancet. Infectious diseases.

1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS

P. Marcellin, P. Thuluvath, G. Everson, 2013 .

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

V. de Lédinghen, G. Dore, S. Pol, 2015, Gastroenterology.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

P. Thuluvath, G. Everson, S. Pol, 2012, The Lancet. Infectious diseases.